Bladder Fiducial Markers and Multiparametric-MRI (Mp-MRI) to Optimize Bladder Chemo-radiotherapy

Not Applicable

Recruiting

• Conditions: Bladder Cancer; Neoplasms; Urinary Bladder Neoplasm; Urologic Neoplasms; Urinary Bladder Diseases
• Interventions: Procedure: Fiducial marker placement; Diagnostic Test: Multiparametric MRI (mpMRI)

• Registration Number: NCT04442724
• Lead Sponsor: Cedars-Sinai Medical Center

Brief Summary

The purpose of this study is to examine the usefulness of implanting small 24-K gold fiducial markers around a bladder tumor site, so that a Radiation Oncologist can identify the original tumor location at the time of radiation treatment. Other goals of the study include assessing whether a new MRI imaging technology can help with detection of bladder cancer earlier and more accurately when evidence of bladder cancer is not visible by scope.

Detailed Description

This study of fiducial markers in patients with localized muscle-invasive bladder cancer will enroll patients electing bladder preservation with tri-modal therapy.

24-K gold fiducial markers will be endoscopically implanted around the tumor resection area to mark the location of the tumor site, into the bladder wall submucosa space under direct visualization via a coaxial needle. The markers are visible on all imaging modalities, including all available on-table imaging (e.g., portal and cone-beam CT) used for radiotherapy. Reliable fiducial marker placement within the bladder may have the potential to advance bladder-sparing management of localized muscle-invasive bladder cancer.

This study will examine the effectiveness of bladder-preserving multi-modal treatment of muscle-invasive bladder cancer with and without fiducial marker placement to guide radiotherapy targeting and to minimize collateral radiation. In addition, this study intends to verify the accuracy and report on the sensitivity and specificity of mp-MRI imaging to detect the presence and location of bladder cancer.

Study Timeline

• Study First Submitted: 2020-06-18
• Study First Submitted QC: 2020-06-19
• Study First Posted: 2020-06-23
• Study Start: 2020-07-01
• Status Verified: 2024-09
• Last Update Submitted: 2025-03-03
• Last Update Posted: 2025-03-05
• Primary Completion: 2025-04
• Study Completion: 2025-06

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Pathologically (histologically or cytologically) proven diagnosis of primary urothelial carcinoma of the bladder. Subjects with mixed histology are required to have a dominant traditional cell carcinoma (TCC) pattern.

• Clinical stage T2-T4a, Nx, M0 considered appropriate for, and electing to receive, chemoradiation of the bladder

• Planned TURBT as part of the normal course treatment, to take place prior to the initiation of chemo irradiation

• Adequate renal function: Serum creatinine < 2 mg/dL OR calculated creatinine clearance (CrCl) > 30ml/min

• Ability to understand and willingness to sign a written informed consent

• Women of child-bearing potential and men must agree to use adequate contraception prior to study entry, during study participation, and for 90 days after study treatment discontinuation

  • Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately

Exclusion Criteria

• Subjects with primary TCC of the ureter, urethra, or renal pelvis, without TCC of the bladder, are not allowed

• Known distant metastatic disease (e.g. pulmonary or hepatic metastases)

  • Subjects with malignant lymphadenopathy in the abdomen or pelvis considered appropriate for radical cystectomy and lymphadenectomy with the goal of complete resection of all malignant disease are allowed

• Patients with bladder abnormalities that preclude safe placement of fiducial markers (i.e. abundant large diverticuli or cellules, active or recurrent urinary infection)

• Planned (or prior history of) definitive bladder irradiation

• Intravesical chemo- or biologic therapy within 6 weeks of first treatment

• Any planned neoadjuvant systemic immunotherapy. Note that prior bacille Calmette-Guerin vaccine (BCG) is not an exclusion

• Clinically significant active infection or uncontrolled medical condition that would preclude participation in study

• Pregnant or nursing women are excluded

• Previous malignancy other than TCC that, in the opinion of the treating investigator, is likely to interfere with protocol treatment

• Individuals with severe renal failure and cannot receive MRI contrast

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Single Arm - Bladder Chemo-Radiotherapy	Fiducial marker placement	Fiducial marker placement \& cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.
Single Arm - Bladder Chemo-Radiotherapy	Multiparametric MRI (mpMRI)	Fiducial marker placement \& cystogram during resection surgery, followed by radiation planning CT scan, mpMRI, chemo-radiation treatment; mpMRI and/or surveillance cystoscopy at 3, 6, and 9 months post-treatment.

Primary Outcome Measures

Name	Time	Method
Bladder volume differential	Baseline, after marker placement (anticipated to occur between study days 0-1)	Change in bladder volumes targeted for high dose radiation (HDR) between the first (Baseline) dose volume histogram (DVH) without the fiducial markers present, compared to the second DVH made after placement of the fiducial markers

Secondary Outcome Measures

Name	Time	Method
Difference in alignment when markers are incorporated into the planning	Radiotherapy treatment period (Days 14-28)	Difference in "on-table" patient alignment under the radiotherapy gantry (in millimeters, in X, Y and Z dimensions) when the patient is aligned daily based on conventional methods only (i.e. fiducial markers are not used for alignment), and when the patient is aligned based on the fiducial markers as the reference.
Net dose radiation to collateral organs differential	Baseline, after marker placement (anticipated to occur between study days 0-1)	comparison of a DVH (Dose Volume Histogram) made without the fiducial markers present, to the second DVH made with the fiducial markers present. This will be measured by net dose (Gy to area and/or volume) to collateral organs
Positive Predictive Value of Multiparametric-MRI (mp-MRI)	at the time of initial TURBT (Day 1), at the initial post-treatment surveillance cystoscopy (3 months post-treatment)	percentage of actual positive sites among those predicted positive by mpMRI

Trial Locations

Locations (3)

Cedars-Sinai Medical Center (CSMC); 🇺🇸 Los Angeles, California, United States

University of California Los Angeles; 🇺🇸 Los Angeles, California, United States

Harvard School of Medicine/Massachusetts General Hospital (MGH); 🇺🇸 Boston, Massachusetts, United States